
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Glp-1 Receptor Agonist Market**

According to Intelli, the U.S. Glp-1 Receptor Agonist Market size was valued at USD 34,626.45 Million in 2024 and is projected to reach USD 1,16,725.54 Million by 2032, growing at a CAGR of 16.93% from 2025 to 2032.



Glucagon-like peptide 1 (GLP-1) receptor agonists are a groundbreaking class of medications that have transformed the management of type 2 diabetes and obesity. By mimicking the action of (GLP-1), a naturally occurring hormone, these drugs work to regulate blood sugar levels, enhance insulin secretion, and slow gastric emptying. As a result, they not only improve glycemic control but also lead to reduced appetite and enhanced feelings of fullness, helping patients to naturally reduce their food intake. This dual action makes GLP-1 receptor agonists an invaluable treatment for managing both metabolic disorders simultaneously, offering a more comprehensive approach to care. Their ability to address both metabolic conditions has made them a cornerstone in modern endocrinology, with ongoing research exploring their potential in other areas such as cardiovascular health. As the treatment landscape evolves, GLP-1 receptor agonists continue to demonstrate remarkable promise in improving patient outcomes and quality of life.

**U.S. Glp-1 Receptor Agonist Market Definition**

**​**The U.S. GLP-1 receptor agonist market refers to the segment of the pharmaceutical industry focused on medications that activate the GLP-1 receptor. The U.S. GLP-1 receptor agonist market represents a dynamic and rapidly expanding segment within the pharmaceutical industry, reflecting significant advancements in the treatment of metabolic disorders. This market comprises of prominent drugs including semaglutide, liraglutide, and tirzepatide.

**U.S. Glp-1 Receptor Agonist Market Overview**

The U.S. GLP-1 receptor agonist market is witnessing robust growth, primarily fueled by a combination of clinical demand, technological advancement, and evolving treatment strategies. A major driver is the rising prevalence of type 2 diabetes and obesity, which has created an urgent need for effective dual-purpose therapies. Another key driver is the advancement in drug formulation technologies, particularly the introduction of once-weekly injectable options and the emergence of oral GLP-1 receptor agonists. These innovations have significantly enhanced treatment convenience and patient adherence by A close-up of hands holding a tablet and a pen

Description automatically generatedreducing dosing frequency and offering less invasive administration methods. Additionally, growing awareness among healthcare providers and patients about the comprehensive benefits of GLP-1 therapies is accelerating their adoption. Lastly, substantial investment in research and development by leading pharmaceutical companies such as Novo Nordisk and Eli Lilly is playing a crucial role in driving market growth.

**U.S. Glp-1 Receptor Agonist Market Segmentation**

The U.S. GLP-1 receptor agonist market is typically segmented based on several key factors that help define the landscape and growth opportunities within the industry.

**U.S. Glp-1 Receptor Agonist Market, By Drug Type**

* **Semaglutide**
* **Liraglutide**
* **Dulaglutide**
* **Exenatide**
* **Tirzepatide**

Semaglutide, marketed under the brand names Ozempic for type 2 diabetes and Wegovy for obesity, emerged as the leading drug in the U.S. GLP-1 receptor agonist market in 2023, capturing around 40% of the total market share. This strong performance reflects its clinical effectiveness, widespread adoption, and growing demand for dual-action therapies that address both glycemic control and weight management. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, has rapidly gained traction since its approval. Liraglutide (Victoza and Saxenda) and exenatide (Byetta and Bydureon), while still utilized, have seen a decline in market share due to the emergence of newer, more efficacious treatments. Overall, the market is increasingly favoring drugs that offer enhanced efficacy, convenient dosing schedules, and broader therapeutic benefits.​

**U.S. Glp-1 Receptor Agonist Market, By Application**

* **Type 2 Diabetes**
* **Obesity/Weight Management**
* **Cardiovascular Risk Reduction**

The U.S. GLP-1 receptor agonist market is segmented by application into type 2 diabetes, obesity/weight management, and cardiovascular risk reduction, each reflecting a growing A close-up of hands holding a tablet and a pen

Description automatically generatedtherapeutic need and expanding use case for these medications. Type 2 diabetes segment continues to hold the largest market share due to the high prevalence of diabetes in the U.S. and the clinical effectiveness of GLP-1 therapies in reducing HbA1c levels. Obesity/Weight Management segment is witnessing rapid growth, driven by rising obesity rates, growing awareness of weight-related health risks, and the demonstrated efficacy of these drugs in supporting sustained weight loss. Emerging evidence shows that certain GLP-1 receptor agonists also offer cardiovascular benefits, such as lowering the risk of major adverse cardiovascular events (MACE) in high-risk populations. As clinical guidelines increasingly support their use in cardiometabolic care, this application is expected to gain more traction in the coming years, further expanding the market’s therapeutic scope.

**U.S. Glp-1 Receptor Agonist Market, By Route of Administration**

* **Injectable**
* **Oral**

The U.S. GLP-1 receptor agonist market is primarily dominated by injectable formulations, which have been the standard route of administration since the introduction of these therapies. However, the market is gradually evolving with the introduction of oral formulations like Rybelsus (oral semaglutide), which provide a more patient-friendly alternative, especially for individuals averse to injections. Although still a smaller segment, oral GLP-1 receptor agonists are expected to gain significant momentum due to their ease of administration and the potential to improve treatment adherence, particularly in the early stages of therapy.

**U.S. Glp-1 Receptor Agonist Market, By Distribution Channel**

* **Hospital Pharmacies**
* **Retail Pharmacies**
* **Online Pharmacies**

The U.S. GLP-1 receptor agonist market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are a significant channel, particularly for patients starting new treatments or requiring specialized care, as healthcare providers often prescribe these medications in clinical settings. Retail pharmacies are the most common point of sale, with patients filling prescriptions at local pharmacies, making this the dominant distribution channel. Online A close-up of hands holding a tablet and a pen

Description automatically generatedpharmacies have seen a rapid rise in recent years, driven by the increasing demand for convenience and home delivery services. As the market expands, all three distribution channels will continue to play vital roles in ensuring broad patient access and improving convenience for those using these therapies.

**Key Players**

The “U.S. GLP-1 receptor agonist market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca, Pfizer Inc., Amgen Inc., Bristol Myers Squibb, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals, Medtronic, Inc., Biogen Inc., Astellas Pharma US, Abbott Laboratories, Horizon Therapeutics, Bayer HealthCare, among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, Eli Lilly launched orforglipron, an oral GLP-1 receptor agonist, which showed encouraging results in a Phase 3 trial with 559 participants. The drug led to an average weight loss of 8% and a 1.6% reduction in HbA1c over 40 weeks.
* In 2024, Amgen launched MariTide, a long-acting injection given once a month, designed to support lasting weight loss results.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. GLP-1 receptor agonist market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be A close-up of hands holding a tablet and a pen

Description automatically generatedused to assess the competitive landscape U.S. GLP-1 receptor agonist market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. GLP-1 RECEPTOR AGONIST MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. GLP-1 RECEPTOR AGONIST MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. GLP-1 RECEPTOR AGONIST MARKET, BY DRUG TYPE**

5.1 Overview

5.2 Semaglutide

A close-up of hands holding a tablet and a pen

Description automatically generated5.3 Liraglutide

5.4 Dulaglutide

5.5 Exenatide

5.6 Tirzepatide

**6 U.S. GLP-1 RECEPTOR AGONIST MARKET, BY APPLICATION**

6.1 Overview

6.2 Type 2 Diabetes

6.3 Obesity/Weight Management

6.4 Cardiovascular Risk Reduction

**7 U.S. GLP-1 RECEPTOR AGONIST MARKET, BY ROUTE OF ADMINISTRATION**

7.1 Overview

7.2 Oral

7.3 Injectable

1. **U.S. GLP-1 RECEPTOR AGONIST MARKET, BY DISTRIBUTION CHANNEL**
   1. Overview
   2. Hospital Pharmacies
   3. Retail Pharmacies
   4. Online Pharmacies
2. **U.S. GLP-1 RECEPTOR AGONIST MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. A close-up of hands holding a tablet and a pen

      Description automatically generated Key Developments Strategies
3. **COMPANY PROFILES**

**10.1 Novo Nordisk A/S**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Eli Lilly and Company**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Sanofi S.A.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **AstraZeneca**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  5. **Amgen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Bristol Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Regeneron Pharmaceuticals, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Vertex Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  3. **Medtronic, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Biogen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Astellas Pharma US**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Abbott Laboratories**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Horizon Therapeutics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  8. **Bayer HealthCare**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

12.1 Related Research